Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details
HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance
Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details
HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance
InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings
Advertising, Acquisition And Potential Subscription Model Point To $6PT For Super League Gaming
InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings
Advertising, Acquisition And Potential Subscription Model Point To $6PT For Super League Gaming
'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis
Alzheon's IPO: What You Need To Know
H.C. Wainwright & Co. Recent News
Analyst: Biofuel Company Gevo Could More Than Quadruple Revenue By 2025
What You Should Know About The Drug Approval Valeant Could Receive This Week
Do Any Signs Of Life Remain In OnceMed's Demcizumab Development?
Where Does Anthera Go From Here?
H.C. Wainwright Is Bullish On Cara Therapeutics Shares
Galectin Shares Downgraded As NASH-FX Failure Likely Degrades The Prognosis For NASH-CX
H.C. Wainwright Initiates Mirna At Buy, Sees 135% Upside
H.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics
H.C. Wainwright Downgrades United Therapeutics To Neutral
Cardiome Is A 'Rising Global Spec Pharma Play With Growth Potential'
H.C. Wainwright Initiates Radius Health At Buy, $55 Target
HC Wainwright Upgrades Caladrius Biosciences To Buy, Sets $1.25 Price Target
H.C. Wainwright Triples Celator Valuation, Says Latest Trial Win Is Rare
H.C. Wainwright Still Buying Amarin, Sees DMC Decision By Summer
Biocept Could Double On Liquid Biopsy Leadership: H.C. Wainwright
What's Happening At The ASCO Conference?
H.C. Wainwright Initiates Coverage On Celladon, Cites Impressive Trial Results For Heart Failure Therapy
H.C. Wainwright & Co. Retains Positive Outlook On OXiGENE
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Finjan Holdings, Inc. On Multiple Positive Factors
UPDATE: H.C. Wainwright & Co. Initiates Coverage On PolyMet Mining Corp. (USA) On Large-Scale Minnesota Project
Threshold Pharmaceuticals, Inc. Shares Jump Amid H.C. Wainwright Initiation
UPDATE: H.C. Wainwright & Co. Initiates Coverage On MELA Sciences On Commercialization Strategy Change